Phase 1 Results for a Parkinson’s Vaccine

Phase 1 Results for a Parkinson’s Vaccine
Last week the Austrian biotech company AFFiRiS published the results of their Phase l clinical trial testing the safety and tolerability of a vaccine treatment for Parkinson's. The therapy - called PD01A - targets a toxic form of the protein alpha-synuclein, which is believed to be involved in the underlying biology of Parkinson's. Alpha-synuclein is a common protein found throughout ... read more
Source: The Cure Parkinson’s TrustPublished on 2020-06-22